Zobrazeno 1 - 10
of 832
pro vyhledávání: '"Kenneth W. Mahaffey"'
Autor:
Josephine Harrington, Anne S. Hellkamp, Kenneth W. Mahaffey, Günter Breithardt, Jonathan L. Halperin, Graeme J. Hankey, Richard C. Becker, Christopher C. Nessel, Scott D. Berkowitz, Keith A. A. Fox, Daniel E. Singer, Shaun G. Goodman, Manesh R. Patel, Jonathan P. Piccini
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 11 (2024)
Background Days alive out of hospital (DAOH) is an objective and patient‐centered net benefit end point. There are no assessments of DAOH in clinical trials of interventions for atrial fibrillation (AF), and it is not known whether this end point i
Externí odkaz:
https://doaj.org/article/a5fb44f1354d4d29a8e3aab8c544798b
Autor:
Abhinav Sharma, Amir Razaghizad, Abdulaziz Joury, Adeera Levin, Harpreet S. Bajaj, G. B. John Mancini, Norman C. Wong, April Slee, Fernando G. Ang, Wally Rapattoni, Brendon L. Neuen, Clare Arnott, Vlado Perkovic, Kenneth W. Mahaffey
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 3 (2024)
Background This study evaluated the effects of canagliflozin in patients with type 2 diabetes with and without prevalent cardiovascular disease (secondary and primary prevention). Methods and Results This was a pooled participant‐level analysis of
Externí odkaz:
https://doaj.org/article/859194b3dcd443bf875f3d7f0a7d9fcb
Autor:
Giulia Ferrannini, Carol Pollock, Andrea Natali, Yshai Yavin, Kenneth W. Mahaffey, Ele Ferrannini
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-10 (2023)
Abstract Background Obesity is an independent risk factor for cardiovascular disease (CVD) in patients with type 2 diabetes (T2D). However, it is not known to what extent weight fluctuations might be associated with adverse outcomes. We aimed at asse
Externí odkaz:
https://doaj.org/article/fce672c1b3eb4cc994ec7692bc3da35a
Autor:
Robert A. Fletcher, Clare Arnott, Patrick Rockenschaub, Aletta E. Schutte, Lewis Carpenter, Muthiah Vaduganathan, Rajiv Agarwal, George Bakris, Tara I. Chang, Hiddo J. L. Heerspink, Meg J. Jardine, Kenneth W. Mahaffey, Bruce Neal, Carol Pollock, Min Jun, Anthony Rodgers, Vlado Perkovic, Brendon L. Neuen
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 12, Iss 13 (2023)
Background Sodium glucose cotransporter‐2 inhibitors reduce systolic blood pressure (SBP), but whether they affect SBP variability is unknown. There also remains uncertainty regarding the prognostic value of SBP variability for different clinical o
Externí odkaz:
https://doaj.org/article/3075bc7abafb43759d117a083ff6e2ac
Autor:
Sok Cin Tye, Niels Jongs, Steven G. Coca, Johan Sundström, Clare Arnott, Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey, Priya Vart, Hiddo. J. L. Heerspink
Publikováno v:
Cardiovascular Diabetology, Vol 21, Iss 1, Pp 1-12 (2022)
Abstract Background Sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of kidney and heart failure events independent of glycemic effects. We assessed whether initiation of the SGLT2 inhibitor canagliflozin guided by multivariable pre
Externí odkaz:
https://doaj.org/article/9ab201997da946b29c0687e277525199
Autor:
Ashish Sarraju, Clark Seninger, Vijaya Parameswaran, Christina Petlura, Tamara Bazouzi, Kiranbir Josan, Upinder Grewal, Thomas Viethen, Hardi Mundl, Joachim Luithle, Leonard Basobas, Alexis Touros, Michael J. T. Senior, Koen De Lombaert, Kenneth W. Mahaffey, Mintu P. Turakhia, Rajesh Dash
Publikováno v:
npj Digital Medicine, Vol 5, Iss 1, Pp 1-7 (2022)
Abstract The Coronavirus Disease 2019 (COVID-19) pandemic curtailed clinical trial activity. Decentralized clinical trials (DCTs) can expand trial access and reduce exposure risk but their feasibility remains uncertain. We evaluated DCT feasibility f
Externí odkaz:
https://doaj.org/article/984329d31e27451a98b54ad847696b8f
Autor:
Paul J. Wang, Ying Lu, Kenneth W. Mahaffey, Amy Lin, Daniel P. Morin, Samuel F. Sears, Mina K. Chung, Andrea M. Russo, Bryant Lin, Jonathan Piccini, Mellanie True Hills, Caroline Berube, Krishna Pundi, Tina Baykaner, Gotzone Garay, Karma Lhamo, Eli Rice, Idean A. Pourshams, Rushil Shah, Paul Newswanger, Katie DeSutter, Julio Cesar Nunes, Michelle A. Albert, Kevin A. Schulman, Paul A. Heidenreich, T. Jared Bunch, Lee M. Sanders, Mintu Turakhia, Abraham Verghese, Randall S. Stafford
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 12, Iss 3 (2023)
Background Oral anticoagulation reduces stroke and disability in atrial fibrillation (AF) but is underused. We evaluated the effects of a novel patient‐clinician shared decision‐making (SDM) tool in reducing oral anticoagulation patient's decisio
Externí odkaz:
https://doaj.org/article/e1046eb2f4e54ef7816c1061fa832f5a
Autor:
Bryan J. Bunning, Haley Hedlin, Jonathan H. Chen, Jody D. Ciolino, Johannes Opsahl Ferstad, Emily Fox, Ariadna Garcia, Alan Go, Ramesh Johari, Justin Lee, David M. Maahs, Kenneth W. Mahaffey, Krista Opsahl-Ong, Marco Perez, Kaylin Rochford, David Scheinker, Heidi Spratt, Mintu P. Turakhia, Manisha Desai
Publikováno v:
Journal of Clinical and Translational Science, Vol 7 (2023)
Abstract Introduction: Clinical trials provide the “gold standard” evidence for advancing the practice of medicine, even as they evolve to integrate real-world data sources. Modern clinical trials are increasingly incorporating real-world data s
Externí odkaz:
https://doaj.org/article/cb1f2d8d07514786bb466e2494aabc6b
Autor:
Jing‐Wei Li, Clare Arnott, Hiddo J. L. Heerspink, Qiang Li MBiostat, Christopher P. Cannon, David C. Wheeler, David M. Charytan, Jennifer Barraclough, Gemma A. Figtree, Rajiv Agarwal, George Bakris, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol Pollock, Hong Zhang, Bernard Zinman, Kenneth W. Mahaffey, Vlado Perkovic, Bruce Neal, Meg J. Jardine
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 16 (2022)
Background The sodium‐glucose cotransporter 2 inhibitor canagliflozin reduced the risk of first cardiovascular composite events in the CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) trial. In
Externí odkaz:
https://doaj.org/article/46cbfff7ef724eea8154c25524ea230a
Autor:
Francis E. Ugowe, MD, Anne S. Hellkamp, MS, Allen Wang, BS, Richard C. Becker, MD, Scott D. Berkowitz, MD, Günter Breithardt, MD, Keith A.A. Fox, MB ChB, Jonathan L. Halperin, MD, Graeme J. Hankey, MD, Kenneth W. Mahaffey, MD, Christopher C. Nessel, MD, Daniel E. Singer, MD, Manesh R. Patel, MD, Jonathan P. Piccini, MD, MHS, FHRS
Publikováno v:
Heart Rhythm O2, Vol 2, Iss 3, Pp 215-222 (2021)
Background: Insulin use may be a better predictor of stroke risk and morbidity and mortality than diabetes in patients with atrial fibrillation (AF). Objectives: Determine if the increased risk of stroke observed in patients with AF and diabetes is r
Externí odkaz:
https://doaj.org/article/6a0db23014864b818546be226fa651ca